2. Components and processing methods of methylene diphenylene desorbing management in a flexible and limited form. The compound includes a polymer matrix including methylaniline or a salt acceptable for the drug, and at least one acrylic polymer which does not react with methylaniline. In addition, a method of transcutaneous management or treatment of attention deficit disorder (TDA) and / or hyperactivity disorder (tdah) with a synthetic substance,Post abdominal tachycardia or narcolepsy Claim 3: the composition of claim 1, wherein the polymer matrix basically comprises a first non reactive acrylic polymer, a second non reactive acrylic polymer, and an alternative acrylic non reactive polymer, There are also methoxyformates or pharmaceutically acceptable salts 4. Claim 4: according to any one of the requirements of 1-3, non reactive acrylic polymer (s) includes one or more single isomers selected from the following groups: methyl acrylate, methyl methacrylate,Butyl acrylate, butyl methacrylate, butyl acrylate, hexilo acrylate, diethylbutyl methacrylate, butyl diethylacrylate, isooctyl acrylate, isooctyl methacrylate, diethylhexyl acrylate, diethylhexyl acrylate, dodecene acrylate, dodecene nitrile acrylate, butadiene ester, dodecyl acrylate, dodecyl methacrylate, Tributylacrylic acid, tributylacrylic acid, acrylamide. Requirement 5: the composition required by requirement 4,At least one non reactive acrylic polymer includes methyl acrylate and 2-ethyl Hydroxy Acrylate. Claim 8: the composition claimed in claims 1-7, wherein the polymer matrix is basically composed of (a) the first non reactive methyl acrylate polymer, including 50% methyl acrylate monomer and 50% 2-ethyl acrylate monomer, based on the weight of the first acrylic polymer； (b) The second non reactive acrylic polymer includes monomers of methylmethacrylic acid, 2-ethylhydroxyacrylic acid, butylacrylic acid and amides,(c) Methylbenzoic acid or a pharmaceutically acceptable salt. 11. Claim 23: the compo
